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Interest  in  the  alternate  or  C3  shunt complement pathway  has  recently been 
generated by a  number of reports  (1-5). Its presence in invertebrates points to  a 
primitive phylogenetic appearance (6). The C3 shunt can be triggered by high molec- 
ular weight polysaccharides in a  manner reminiscent of  the properdin system  (7). 
Once activated by cobra venom, erythrocytes and other cells can be lysed in the ab- 
sence of specific antibody (3). This mechanism may also be set into motion by im- 
munoglobulins to  which  the  classical  C  sequence  is  indifferent  (2-4).  Moreover, 
cleavage of C3 via the alternate pathway results in the production of biologically  active 
substances (3, 8). 
To facilitate further studies of the C3 shunt system, a hemolytic assay has 
been described (3, 5). It has now been used to measure the C3 shunt hemolytic 
activity in the sera of patients with neoplastic and other diseases.  The data 
suggest that human neoplasia may be associated with changes in the C3 shunt 
complement system, particularly as it concerns one of its major components, 
the C3 proactivator (3). 
Materials and Methods 
Sera. Sera from patients with a variety of malignant tumors (colon and breast carcinoma, 
sarcoma, leukemia, etc.) were obtained through the generous cooperation of Doctors Lloyd Old 
and Germain Trempe of the Sloan-Kettering Institute for Cancer Research in New York. Sera 
from healthy adults were obtained from laboratory personnel and donors at the blood bank of 
the New York University Medical Center. Sera from hospitalized patients with diseases other 
than cancer (hypertension, cardiac disease, cirrhosis, thrombotic phenomena, etc.) were made 
available through  the kind assistance of Dr.  Gerald Salen of the Veterans Administration 
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Hospital in Manhattan and Dr. Franco Cavallo of Bay Shore, Long Island, N.Y. All the spec- 
imens were stored at -- 70°C until used. 
CVFAHso Assay.--This assay was performed as in reference 5. Briefly, cobra venom factor 
(CVF; Cordis Laboratories. Miami, Fla.)  was incubated with several dilutions of the test 
serum in Mg  2+ Veronal-buffered  saline (VBS) before the addition of guinea pig C and a suspen- 
sion of guinea pig erythrocytes,  both rendered 0.02 •  in respect to ethylenediaminetetraacetate 
(EDTA). Mter further incubation the degree of lysis was measured spectrophotometrically. 
The term CVFAHs0 (CVF acfivable hemolysis) units per milliliter refers to the reciprocal of 
the serum dilution required to lyse 50% of the guinea pig red cells (5). 
Inulin Treatment.--0.5 ml of undiluted serum was incubated with 0.5 ml of inulin suspension 
(5  mg)  in Mg2+-VBS  for 30  min at 37°C.  The tubes were centrifuged and the supernates 
assayed for CVFAHs0. 
TABLE  I 
Distribution of CVFAHso Titers 
Clinical status  20-30  /  30-40  40-50  50-60  60-70  70-80  >80 
A) Healthy 
B) Hospitalized 
Noncancer 
C) Hospitalized 
Cancer 
Total  10-20 
Number  81  5 
Number  50  6 
131 
Per cent  100  8.4 
Number  87  0 
Per cent  100  0 
30 
19 
37.4 
14 
16.1 
Units/ml serum 
20  12 
12  9 
24.4  16.0 
19  21 
21.8  24.1 
7  4 
3  1 
7.6  3.8 
13  11 
14.9  12.6 
2  1 
0  0 
1.5  0.8 
5  4 
5.7  4.6 
Mean 4- SD: group A, 35.6 -4- 14.5; group B, 32.3 -4- 11.5; group C, 47.7 4- 18.2. 
Immunoelectrophoresis.--This  procedure was  carried  out  with  1.0%  agarose in  Veronal 
buffer (pH =  8.6, #  =  0.05) in 0.01 M  EDTA for 120 rain at room temperature with a potential 
gradient of 5 v/cm. The lines of precipitation were developed with monospecific goat anti- 
human  C3  (Cordis Laboratories)  and with rabbit anti-human/~2  glycoprotein II  (Behring 
Diagnostics, Somerville, N. J.). 
RESULTS  AND  DISCUSSION 
The  data  in  Table  I  show  that  the  mean  CVFAHs0  titers  for  the  healthy 
donors,  group  A,  and  for  the  patients with non-neoplastic  diseases,  group  B, 
were  similar,  i.e.,  35.6  and  32.3  CVFAHso  units/ml,  respectively  (t  =  1.44, 
P  >  0.1). Nor did the distribution  frequencies of the titers in these two popula- 
tions differ significantly  (X  2 =  2.1, _P >  0.8). 
In contrast,  the mean serum titer for the cancer group  (group C), 47.7,  was 
significantly  higher  than  that  for  group  A  (t  =  4.76,  P  <  0.001),  group  B 
(t  =  6.02,  P  <  0.001),  and  for the  combined value  of group A  plus  group B 
(t  =  5.81, P  <  0.001).  Likewise, the distribution  profile of the serum titers for 
the  cancer  group  differed  from  that  of the  other  two  groups,  C  vs.  A  +  B; 
(X  2 =  24.56,  P  <  0.001)  (Fig.  1 A). 952  COmmA  VENOM-INDUCED  HEMOLYSIS 
The  contribution  of the cancer  and  noncancer  sera to each  titer interval  was 
expressed as the per cent of the total number of sera within that class, Fig. 2 A. 
The  sera of  the  cancer patients contributed most  of  the  higher titer values. 
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FIG. 1.  Distribution of CVFAHs0 titers in sera of cancer and noncancer donors before and 
after inulin treatment. 
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Fio. 2.  Per cent contribution of cancer and noncancer sera to each titer class before and 
after inulin treatment. 
However  a  considerable overlap  between  the  two  sets  of  data  is  apparent 
(Figs. 1 A  and 2 A). 
The inference that sera from cancer patients may differ from those in the con- 
trol groups in respect to the C3 shunt system was strengthened by other experi- 
ments.  Since  the  interaction of  fresh  serum  with  inulin results  in  marked /¢IELCHIORRE  BRAI  AND  ABRAHAM  G.  OSLER  953 
alteration of the  C3  proactivator (3,  5)  we examined  the  effect of this poly- 
saccharide on CVFAHa0 titers. Inulin treatment reduced the mean titer of the 
sera in groups A  and B  to the same extent (t =  0.67, P  >  0.6). These data have 
therefore been pooled for the comparisons shown in Table II and Figs. 1 B  and 
2 B. Inulin treatment heightened the differences between the cancer and control 
groups  in  respect  to  mean  titer  values  (t  =  6.69,  P  <  0.001),  distribution 
frequencies (X  2 =  28.78, P  <  0.0005),  and hemolytic activity losses (Figs. 1 B 
and 2 B,  and Tables II and III). 
Differences between  the cancer  and noncancer  sera were  also demonstrable 
TABLE  II 
13istribution of CVFAHso Tilers after Inulin Treatment 
Clinical status  Total no.  <10  10-20  20-30  30-40  40-50  >50 
Units/ml serum 
Healthy  and noncancer  64  5  36  20  2  1  0 
Cancer  43  0  6  17  9  6  5 
The  means  4-  sn  for  the  control  and  cancer  group  were  18.0  -4-  7.7  and  31.3  -4-  11.3 
respectively; t  =  6.69, P  <  0.001. 
TABLE  III 
Activity Losses after Inulin Treatment 
Per cent loss 
Clinical status  TotM no. 
0-20  20-30  30-40  40-50  >50 
Noncancer  64  0  4  15  36  19 
Cancer  43  11  13  12  2  5 
X  2 =  36.52, P  <  0.0005. 
The mean  losses in  activity due  to inulin  treatment of the noncancer  and  cancer  sera 
were 46.4  4- 12.2 and 29.4 4- 12.8% respectively; t  =  6.82, P  <  0.001. 
by  immunoelectrophoresis  as  exemplified  in  Fig.  3.  Heavier  precipitates 
generally appeared with the cancer sera after development with  an antiserum 
to human f12  glycoprotein II. After inulin  treatment  the  line of precipitation 
formed  by the  control sera,  in  the ~  region,  was  largely converted  to  one of 
3'  mobility. Here,  too,  the cancer  sera behaved differently in  that  conversion 
as a consequence of inulin treatment was less complete (Fig. 3). The differences 
in the intensity of the precipitates and the extent of conversion generally agreed 
with the CVFAH~0 titers. C3 was partially cleaved in all sera after inulin treat- 
ment  (Fig. 3). 
22  sera in the control groups  and  17  cancer sera were assayed concurrently 
for  CVFAHs0  and hemolytic C  titers, CHs0.  The latter were performed as in 
reference 2 with sensitized sheep erythrocytes. No significant difference in mean 954  COBRA  VENOM-INDUCED  HEMOLYSIS 
CHs0  titers was observed between the two groups of sera (t  --  1.2,  _P  >  0.2). 
The correlation coefficients for the two assays in the cancer and control groups 
were r  =  0.22  and 0.44,  respectively. 
The  present findings indicate that,  as  a  group,  the  sera of cancer patients 
exhibit a different C3 shunt reaction pattern than do the sera of healthy donors 
or those with non-neoplastic diseases. The cancer sera generally  manifest greater 
hemolytic activity after admixture with  a  cobra venom protein,  the terminal 
complement components (C-EDTA), and unsensitized guinea pig erythrocytes. 
In addition, they retain relatively more hemolytic activity than do the controls 
after the incubation with inulin  (Figs.  1  and  2).  The higher titers of the un- 
treated  and inulin-treated cancer sera may reflect increased levels of C3  pro- 
FIG. 3.  Immunoelectrophoresis  of cancer sera (c) and controls  (nc). The results obtained 
with six sera are shown before (con, upper three wells) and after treatment with inulin  (inu, 
lower three wells). The troughs contained anti-human 32 glycoprotein (a-bg) or anti-human C3 
(a-c3).  The numbers  beside the designations  c or nc refer  to the CVFAHs0 titers for these 
specimens. 
activator  as  judged  by  immunoelectrophoresis  (Fig.  3).  This  interpretation, 
consistent as it is with the present data,  does not exclude the possibility that 
other factors (9,  10) may account in part for the observed differences. Further 
characterization of the  reaction steps in  this  sequence  coupled with  detailed 
clinical studies are required to evaluate the implications of these findings. 
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